Furthermore, in the clinicopathological and prognosis analyses, upregulated MMP14 was significantly associated with a higher tumor stage (p = 0.007), a shorter DSS survival time (HR = 1.73, p = 0.01), a shorter PFS time (HR = 1.38, p = 0.02), and a significantly shorter RFS time (HR = 1.47, p = 2.48 × 10−3). This evidence concerns the gene MMP14 and neoplasm.